LIPOSOMAL COMPOSITION COMPRISING A STEROL-MODIFIED LIPID AND A PURIFIED MYCOBACTERIAL LIPID CELL WALL COMPONENT AND ITS USE IN THE DIAGNOSIS OF TUBERCULOSIS
    1.
    发明申请
    LIPOSOMAL COMPOSITION COMPRISING A STEROL-MODIFIED LIPID AND A PURIFIED MYCOBACTERIAL LIPID CELL WALL COMPONENT AND ITS USE IN THE DIAGNOSIS OF TUBERCULOSIS 审中-公开
    包含甾体修饰脂质和纯化的脂肪细胞脂肪细胞壁组分的脂质组合物及其在管状结肠癌诊断中的应用

    公开(公告)号:US20150111219A1

    公开(公告)日:2015-04-23

    申请号:US14406636

    申请日:2013-06-07

    Abstract: A liposomal composition comprising a sterol-modified lipid and a purified mycobacterial lipid cell wall component or analog or derivative thereof is described. The composition is useful as a lipid antigen-presenting vehicle for the detection of lipid antigen specific biomarker antibodies in antibody containing biological samples in the diagnosis of active tuberculosis. The purified lipid cell wall component is typically a purified mycolic acid or a mixture of mycolic acids from a mycobacterium that produces mycolic acids. The sterol-modified lipid is typically a phospholipid.

    Abstract translation: 描述了包含固醇修饰的脂质和纯化的分枝杆菌脂质细胞壁组分或其类似物或衍生物的脂质体组合物。 该组合物可用作在用于诊断活动性结核病的抗体含有生物样品中的脂质抗原特异性生物标志物抗体的脂质抗原呈递载体。 纯化的脂质细胞壁组分通常是纯化的霉菌酸或来自分枝杆菌的霉菌酸的混合物,其产生霉菌酸。 甾醇修饰的脂质通常是磷脂。

    METHOD OF DIAGNOSING TUBERCULOSIS
    2.
    发明申请

    公开(公告)号:US20200150130A1

    公开(公告)日:2020-05-14

    申请号:US16726429

    申请日:2019-12-24

    Abstract: Immobilising isolated mycolic acid antigens of tuberculous mycobacterial origin or a synthetic analogue thereof on a screen-printed electrode by binding of the antigens to a self-assembled monolayer comprising a thiolated hydrophobic substance to produce immobilized mycolic acids antigens in the form of a mycolic acid antigen-containing self-assembled monolayer coating on a surface of the electrode

    Method of diagnosing tuberculosis

    公开(公告)号:US10551391B2

    公开(公告)日:2020-02-04

    申请号:US14891490

    申请日:2014-05-15

    Abstract: Mycolic acid antigen containing liposomes, and an electrode immobilised antigens of tuberculous mycobacterial origin are produced. A diagnostic sample from a human suspected of having tuberculosis is diluted and divided into first and second samples. A control sample comprising the first sample and a redox probe is exposed to the liposomes. A test sample comprising the second sample and a redox probe is exposed to liposomes not containing mycolic acid antigens. The control sample is contacted with the immobilised antigens to allow antibodies therein to bind to the antigens. The test sample is contacted with the immobilised antigens to allow any antibodies therein to bind to the antigens. The degree of binding in the samples is compared by electrochemical impedance spectroscopy. Any observed lesser binding by the control sample is an indicator of antibodies to the antigens in the diagnostic sample, indicating tuberculosis in the human.

Patent Agency Ranking